Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has started shipping bupropion hydrochloride extended release tablets. This product was recently approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA). These bupropion hydrochloride extended release tablets, 100 mg, 150 mg, and 200 mg, are therapeutically equivalent to GlaxoSmithKline's Wellbutrin SR® Extended Release tablets. These strengths of generic bupropion hydrochloride extended release tablets have annual sales of approximately $300 million in the US. Bupropion Hydrochloride (SR) Extended Release tablets are indicated for the treatment of major depressive disorder.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.